RA Capital Management L.P. Buys 1,200,000 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

RA Capital Management L.P. boosted its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 13.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,365,652 shares of the company's stock after buying an additional 1,200,000 shares during the quarter. Janux Therapeutics makes up approximately 7.3% of RA Capital Management L.P.'s investment portfolio, making the stock its 3rd biggest holding. RA Capital Management L.P. owned about 19.75% of Janux Therapeutics worth $554,977,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Adage Capital Partners GP L.L.C. grew its position in shares of Janux Therapeutics by 47.6% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,061,750 shares of the company's stock worth $163,926,000 after buying an additional 986,750 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Janux Therapeutics by 596.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,109,978 shares of the company's stock worth $59,429,000 after purchasing an additional 950,557 shares during the last quarter. FMR LLC grew its holdings in Janux Therapeutics by 10.8% in the fourth quarter. FMR LLC now owns 8,669,941 shares of the company's stock worth $464,189,000 after purchasing an additional 845,266 shares during the last quarter. Lord Abbett & CO. LLC lifted its holdings in shares of Janux Therapeutics by 80.2% during the 4th quarter. Lord Abbett & CO. LLC now owns 1,267,803 shares of the company's stock valued at $67,878,000 after purchasing an additional 564,322 shares during the last quarter. Finally, Wellington Management Group LLP boosted its position in shares of Janux Therapeutics by 3,592.9% in the 4th quarter. Wellington Management Group LLP now owns 535,396 shares of the company's stock worth $28,665,000 after purchasing an additional 520,898 shares in the last quarter. Institutional investors own 75.39% of the company's stock.

Janux Therapeutics Trading Up 2.6 %

NASDAQ JANX traded up $0.83 on Friday, hitting $32.88. 825,257 shares of the company's stock traded hands, compared to its average volume of 847,327. The firm's 50-day moving average price is $29.80 and its two-hundred day moving average price is $42.52. The firm has a market capitalization of $1.95 billion, a PE ratio of -28.10 and a beta of 3.27. Janux Therapeutics, Inc. has a 1-year low of $22.52 and a 1-year high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. On average, research analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Insider Transactions at Janux Therapeutics

In related news, insider Andrew Hollman Meyer sold 3,334 shares of the stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $42.29, for a total transaction of $140,994.86. Following the sale, the insider now directly owns 82,139 shares of the company's stock, valued at approximately $3,473,658.31. This represents a 3.90 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Ra Capital Management, L.P. acquired 110,206 shares of the business's stock in a transaction on Friday, March 7th. The stock was purchased at an average cost of $31.02 per share, with a total value of $3,418,590.12. Following the acquisition, the director now directly owns 10,141,287 shares of the company's stock, valued at $314,582,722.74. This represents a 1.10 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold 13,335 shares of company stock worth $454,959 over the last quarter. 29.40% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have commented on JANX. Wedbush reiterated an "outperform" rating and issued a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. Scotiabank decreased their price objective on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a research report on Friday, February 28th. HC Wainwright reiterated a "buy" rating and issued a $70.00 target price on shares of Janux Therapeutics in a research note on Monday, March 3rd. Finally, William Blair restated an "outperform" rating on shares of Janux Therapeutics in a research note on Friday, January 10th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $95.25.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.